

Recent Advances in Understanding Immunity Against Brucellosis: Application for Vaccine Development

Sérgio Costa Oliveira^{*1}, Gilson Costa Macedo¹, Leonardo Augusto de Almeida¹,
Fernanda Souza de Oliveira¹, Angel Oñate², Juliana Cassataro³ and
Guillermo Hernán Giambartolomei³

¹Department of Biochemistry and Immunology, Institute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte-Minas Gerais, Brazil

²Department of Microbiology, Faculty of Biological Sciences, Molecular Immunology Laboratory, Universidad de Concepción, Concepción, Chile

³Instituto de Estudios de la Inmunidad Humoral (CONICET), Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires (UBA), Buenos Aires, Argentina

Abstract: Brucellosis is an important zoonotic disease of nearly worldwide distribution. This pathogen causes abortion in cattle and undulant fever, arthritis, endocarditis and meningitis in human. The immune response against *B. abortus* involves innate and adaptive immunity involving antigen-presenting cells, NK cells and CD4⁺ and CD8⁺ T cells. IFN- γ is a crucial immune component that results from *Brucella* recognition by host immune receptors such as Toll-like receptors (TLRs) that lead to IL-12 production. Although great efforts to elucidate immunity against *Brucella* have been employed, the subset of cells and factors involved in host immune response remains not completely understood. Our group and others have been working in an attempt to understand the mechanisms involved in innate responses to *Brucella*. Understanding the requirements for immune protection can help the design of alternative vaccines that would avoid the drawbacks of currently available vaccines to *Brucella*. This review discusses recent studies in host immunity to *Brucella* and new approaches for vaccine development.

Keywords: *Brucella abortus*, vaccines, innate immunity, cytokines, DNA vaccines, recombinant vaccines, deletion mutants.

1. INTRODUCTION

Brucella spp. are Gram-negative coccobacilli, aerobic, urease positive, non-motile bacteria which cause brucellosis in humans and in a variety of animal species [1]. Among *Brucella* species are *B. melitensis*, *B. abortus*, *B. suis*, *B. canis*, *B. neotomae*, and *B. ovis*. The first four species are pathogenic to humans in decreasing order of severity making brucellosis a zoonotic disease with more than 500,000 new cases reported annually. *Brucella* spp. can persist in unpasteurized dairy products such as raw milk, soft cheese, butter and ice cream. Additionally, consumption of undercooked animal organs such as spleen and liver has been implicated in human infection [2].

Health and sanitary regulations predicated on fear of spreading virulent cattle diseases, such as brucellosis, have limited the marketing opportunities of cattle products between countries. Despite great regulatory efforts worldwide, pathogenic *Brucella* spp. can persist in domestic livestock or free-ranging wildlife. Although vaccination is probably the most economic control measure, administration

of currently available vaccines alone is not sufficient for elimination of brucellosis in any host species [3]. Thus, the development of effective vaccines that completely prevent the infection and protect the different hosts of *Brucella*, is required for elimination of this illness.

As the complete genomic sequences of some *Brucella* species are available, the search for virulence factors is a key approach to understand the mechanisms used by this bacterium to escape the host immune system. Bioinformatic analysis showed that *Brucella* lacks classical virulence-related sequences and genes, such as toxins, type I, II or III secretion systems, pilus biogenesis genes, and others. Our research group has investigated the role of some structural and metabolic components in bacterial pathogenesis using the disrupting gene approach to obtain new attenuated vaccine strains. Additionally, we have dissected some of the pathways involved in *Brucella* recognition by innate immune receptors using knockout mice.

2. IMMUNE RESPONSE AGAINST BRUCELLA

Brucella spp. are facultative intracellular pathogens which resist killing by neutrophils, replicate inside macrophages and in “non-professional” phagocytes and maintain a long lasting interaction with the host cells [4]. As intracellular organisms, protection against *Brucella* infection requires cell-mediated immunity, which includes CD4⁺ and CD8⁺ T lymphocytes, Th1-type cytokines such as IFN- γ and

*Address correspondence to this author at the Laboratory of Immunology of Infectious Diseases, Department of Biochemistry and Immunology, Institute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte-Minas Gerais, 31270-901, Brazil; Tel: +55 31 34092666; E-mail: scozeus@icb.ufmg.br

TNF- α , and activated macrophages and dendritic cells (DC) [5]. Therefore, host control of infection requires a set of cells and factors which together promote a complex response against *Brucella*.

CD8⁺ T cells have the predominant role for optimal protection against *B. abortus* infection. This protection can be performed by a type 1 cytokine profile production, mainly IFN- γ , and lysis of *Brucella*-infected macrophages [6,7]. Lysis of this macrophages releases the bacteria to the extracellular milieu enabling uptake by other activated macrophages in a IFN- γ -rich microenvironment. These cells presents augmented antibruellae mechanisms and are able to destruct the pathogen, inhibiting *Brucella* spread [8]. Moreover, the type 1 cytokines produced by CD8⁺ T cells induce down-regulation of Th2 cytokines and IL-10 [6, 7].

Since mice can develop the symptoms of brucellosis when infected intraperitoneally, they are widely used as experimental model to better understand the infection course, even though mice are not considered natural host of *Brucella*. The infection process in BALB/c and C57BL/10 mice differs in their abilities to induce immune responses and protection against virulent *Brucella* [9-11]. BALB/c mice are more sensitive than C57BL/6 mice to virulent *Brucella* such as *B. melitensis*, *B. abortus*, and *B. suis*. The infection control correlates with the level of IFN- γ produced by CD4⁺ T cells at specific times following infections in these mouse models [9]. Sathiyaseelan *et al.* (2006) [12] demonstrated that BALB/c mice produce IFN- γ in the first week of infection with *B. abortus*, however the level of IFN- γ production decreases and this is consistent with transiently decrease of IL-12R β ²⁺ cells during the course of brucellosis. Also, the administration of recombinant IL-12 restored the ability of BALB/c splenocytes to produce IFN- γ and increases protective immunity. As IFN- γ produced by T cells is vital for control of infection, *Brucella* organisms have to face a second challenge if willing to persist in the host for a long time. Bacteria should be able to inhibit Ag processing and presentation by *Brucella*-containing macrophages to avoid the immunological surveillance of MHC-II restricted IFN- γ -producing CD4⁺ T lymphocytes. Recently, Barrionuevo *et al.* (2008) [13] have demonstrated that infection with *Brucella* species down-modulates expression of MHC-II and Ag presentation on monocytes/macrophages. This phenomenon was induced by L-Omp19, a prototypical *Brucella* lipoprotein and it was dependent of TLR-2 and it was mediated by IL-6.

Brucella species, such as *B. suis* or *B. melitensis*, are able to induce chronic infection and multiply inside human macrophages. Bessoles *et al.* (2009) [14] demonstrated that intramacrophagic *Brucella* multiplication is impaired in presence of CD4⁺iNKT cells. The impairment of *Brucella* growth by CD4⁺iNKT cells requires an interaction with CD1d present on macrophage surface. These authors suggested that CD4⁺iNKT cells can contribute to host control of infection at several levels, indirectly by influencing the development of adaptive immune response through the production of cytokines and directly on the clearance of bacteria through eliminating infected cells and/or killing intracellular bacteria. Also related with the impairment of *Brucella* growth are the T cells of the $\gamma\delta$ subset. These cells are capable of inhibiting *Brucella* growth

through a combination of mechanisms such as cytotoxicity, macrophage activation through cytokine and chemokine secretion and antibacterial effects [15]. Besides, inducing macrophage death and reduction of intracellular *Brucella* through Fas-FasL interactions, the V γ 9V δ 2 T cells, the major subtype of $\gamma\delta$ T cells, also release soluble factors responsible for a bactericidal activity of these cells limiting the spread of this intracellular pathogen [15, 16].

Brucella is also able to survive inside human neutrophils [17,18]. Furthermore, *B. abortus* induced an increase in CD35 and CD11b expression and a decline in CD62L accompanied by IL-8 secretion, a response compatible with neutrophil activation which can lead to tissue damage and pathology associated with human brucellosis. This neutrophil activation also is induced by stimulation with L-Omp19, which is a *Brucella* lipoprotein. Thus, *Brucella* lipoproteins possess pro-inflammatory properties that could contribute to tissue injury and inflammation by direct activation of neutrophils [19].

2.1. The Role of Toll-Like Receptors in *Brucella abortus* Infection

The first line of defensive mechanisms begins with the recognition of pathogen-associated molecular patterns (PAMPs) by pattern recognition receptors (PRRs) [20]. There are several functionally distinct classes of PRRs. The best characterized are the Toll-like receptors (TLRs), which are transmembrane receptors that sense lipids, lipoproteins, proteins and nucleic acids [21]. Recognition of PAMPs by TLRs stimulates the recruitment of a set of intracellular TIR-domain-containing adaptors, including MyD88, TIRAP, TRIF and TRAM *via* TIR-TIR interactions to initiate signaling. MyD88 initiates a cascade that leads to the activation of MAP kinases (MAPKs: ERK, JNK, p38) and the transcription factor NF- κ B to control the expression of inflammatory cytokines genes. TIRAP mediates the activation of a MyD88-dependent pathway downstream of TLR2 and TLR4. Alternatively, TLR3 and TLR4 may recruit TRIF and activate another pathway (TRIF-dependent pathway) that leads to the activation of the transcription factor IRF3 and involves the production of type I IFN, particularly IFN- β . TRAM selectively participates in the activation of the TRIF-dependent pathway downstream of TLR4, but not TLR3. Therefore, each TLR recruits a specific set of TIR domain-containing adaptors, which in turn triggers different transcription factors, controlling innate immune responses and further leading to the development of antigen-specific acquired immunity [22].

Our group has evaluated the role of a number of TLRs and its adaptor molecules as well as cytokine receptors involved in innate immune responses that might be critical in controlling *B. abortus*. Regarding the ability of host TLRs to recognize *Brucella*, there are some contradictory data reported in the literature. We have reported a role for TLR2 and TLR4 on *Brucella* signaling but we only observed the involvement of TLR4 in resistance [23]. Barquero-Calvo *et al.* (2007) [24] observed that TNF- α secretion in macrophages culture infected with *B. abortus* seems to depend somewhat on TLR2 and TLR4, but the signaling by these receptors does not affect the intracellular replication of this pathogen. However, when both TLRs were absent, it

was observed a partially dependence of these molecules, suggesting that signaling by at least one of these receptors is required to prolong host survival. Regarding TLR2, Giambartolomei *et al.* [25] have demonstrated that *B. abortus* lipoproteins Omp16 and Omp19 induced the production of pro- and anti-inflammatory cytokines in THP-1 cell line and this cell activation is TLR2-dependent. *Brucella* Omp19 lipoprotein also has been found to induce the expression of IL-12 and other pro-inflammatory cytokines and up-regulation of cell surface markers in monocytes/macrophages and DC. The cytokine released by DC, including IL-12, was also dependent on TLR2 stimulation [26]. Biological responses induced by *Brucella* lipoproteins were dependent on their lipid moiety since unlipidated Omp19 and Omp16 were unable to stimulate cellular responses. Additionally, we have reported that in murine DC HKBA-induced IL-12 production was TLR9-dependent [27]. It may be also related with the premise that TLR9 is the relevant TLR for controlling *Brucella* infection through specialized dendritic cells acting in concert with other cells for generating IFN- γ [28]. Coppin *et al.* [28] suggested that TLR4 cooperates with TLR9 in *Brucella* detection. Despite the discrepancy on the data demonstrating TLR4-dependent innate responses during *Brucella* clearance *in vivo*, TLR9 has been shown to be the TLR that plays a more prominent role during infection [27].

The molecule MyD88, which is the adaptor molecule for several TLRs and some interleukin receptors, is clearly required for the control of *Brucella* replication in mice [27-29], suggesting that signaling through receptors that use MyD88 is critical to control brucellosis. Our group has investigated the mechanisms involved in MyD88 KO susceptibility and has demonstrated that these animals present impairment on maturation of DC and absence of IL-12 and TNF- α production by macrophage and DC in response to heat killed *B. abortus* (HKBa). IL-12 was shown to be critical to this susceptibility as soon as the treatment with a recombinant virus expressing IL-12 enhances MyD88 KO resistance to *Brucella* [27]. MyD88 is also used by other inflammatory signaling pathways such as IL-1 and IL-18; however, signaling through IL-1R or IL-18R seems to be not necessary for host defense against *Brucella* infection (unpublished results; [29]).

3. Recent Approaches in *Brucella* Vaccine Development

The development of an effective vaccine against brucellosis has been a challenge to scientists around the world. According to Adams (1990) [30], an ideal vaccine against *Brucella* should have the following requirements: i) prevents the bacterium infection in both gender; ii) not provoke disease in vaccinated animals; iii) prevents abortion; iv) promotes long period of protection with only one dose; v) not interfere with serological diagnosis; vi) biologically stable and should not present risk of virulence reversion; vii) not be pathogenic to humans and should not contaminate products derivate from the vaccinated animals; and, besides, viii) it should be produced in large scale.

At moment, three *Brucella* strains have been used in brucellosis prevention: S19, Rev1 e RB51. However, these strains are still far from ideal. Although the smooth strains S19 from *B. abortus* and Rev1 from *B. melitensis* are able to

induce effective levels of protection in cattle and in goat and sheep; respectively, they have some problems. These vaccine strains can cause abortion in pregnant animals and they can be secreted in milk of vaccinated animals. Besides, both of them are pathogenic to humans and interferes with the diagnosis because they possess the LPS contained the intact O-chain. The antibody production against O-chain troubles the differentiation between vaccinated from infected animals [31]. On the other hand, the mutant strain RB51 derivated from *B. abortus*, does not possess intact O-chain which avoid interference in serological diagnosis. Besides, RB51 is stable and is less virulent then the smooth strains [32]. However, this strain is resistant to rifampicin that is the first antibiotic of choice to human brucellosis treatment [33]. Moreover, the immunization effectiveness of RB51 is controversial in different hosts [34].

To solve the problems presented by the currently available vaccines, several efforts have been performed to improve these immunogens. In an attempt to increase the protection given by the rough vaccine strains, Grilló and colleagues (2006) [35] demonstrated that the co-administration of different *Brucella* mutants can confers protection against murine brucellosis. In that study, the investigators produced mutants to O-chain, specifically to *wbka* gene, and to two components regulatory system *bvrS/bvrR*. The vaccination combining the two mutants conferred better levels of protection when compared to the S19 protection. Also, the combination of rough mutants was not able to induce the production of antibodies against the O-chain as the S19 vaccine strain S19.

Arenas-Gamboa *et al.* (2009) [36], using the vaccine strain S19, developed a mutant to *vjbR* gene, which encodes a transcriptional regulator associated to *virB* expression, and it is associated to bacterium virulence and bacterium surveillance inside macrophages. This potential vaccine was delivered in microcapsules as a different delivery system. They reported higher level of protection induced by this vaccination strategy when compared to S19 strain. Besides, inflammation and persistence was also decreased.

Izadjoo and coworkers (2004) [37] evaluated a orally administered live attenuated purine-auxotrophic *Brucella melitensis* mutant strain, WR201. The ability of this mutant strain to elicit cellular and humoral immune responses and to protect mice against intranasal challenge with *B. melitensis* 16M was evaluated. In this report, the strain WR201 was able to induce cellular, humoral and mucosal immune responses. Moreover, oral immunization induced protection against systemic bacterial spread and enhanced clearance of bacteria from the lungs after intranasal challenge. These results suggest that purine auxotrophy is an attractive attenuating strategy for further vaccine development. However, in another study, these researchers showed that WR201 mutant retains its infectivity for reproductive tissues [38]. This tropism may lead to signs and symptoms of disease in man.

In attempt to construct a vaccine against *Brucella ovis* infection which was not capable to interfere in differentiation between vaccinated from infected animals, Grilló *et al.* (2009) [39] tested the deletion of *bp26* gene (CGV26) or both *bp26* and *omp31* genes (CGV2631) in *B. melitensis* Rev 1. *Bp26* and *Omp31* are two proteins that have potential

differential diagnostic interest [40-42]. After subcutaneous administration in rams, the mutants conferred significant protection; however, the level of protection induced by CGV26 was higher than that conferred by Rev.1 and similar to that engendered by Rev.1. These results demonstrated that the CGV26 mutant, associated with an adequate diagnostic strategy, could be a useful alternative to Rev.1 reducing the problem of serological interferences.

Since RB51 does not confer resistance to *B. melitensis* or *B. ovis*, other rough strains have been evaluated as potential vaccine. Recently, Adone and colleagues (2008) [43] described that vaccination with the rough mutant strain B115 from *B. melitensis* engendered significant levels of protection against these species of *Brucella* in BALB/c mice. Even though this mutant can produce cytoplasmatic levels of O-chain, antibodies against LPS were not detected.

The use of *Brucella* specific antigens as potential vaccine candidates has been also exhaustively investigated. The most used strategy is the identification of antigens able to induce a strong cellular immune response [44]. In this regard, some antigens have induced interesting results such as the protein p39 [45], the Cu-Zn superoxide dismutase [46], the ribosomal protein L7/L12 [47-50], the heat shock proteins GroEL and GroES [47], the lumazine synthase [51], Omp-31 [52] and the glyceraldehyde-3-phosphate-dehydrogenase [53].

Recently, it was demonstrated that immunization with non-lipidated (U) forms of recombinant membrane proteins Omp-16 and Omp-19 (U-Omp16 or U-Omp19) induced a T_H1 response, systemic protection in aluminum hydroxide formulation, and oral protection with cholera toxin adjuvant against *B. abortus* infection. Both immunization routes exhibited a similar degree of protection to attenuated *Brucella* vaccines (S19 and RB51, respectively). These results suggest the possible use of these proteins for a subunit vaccine against human and animal brucellosis [54].

The recombinant proteins SurA (a periplasmic peptidyl prolyl *cis-trans* isomerase) and DnaK (a chaperone from HSP70 family) were also evaluated. These proteins were able to induce a robust humoral response, IFN- γ and a cytotoxic response. However, the protection level induced by these proteins is lower than the protection conferred by the live vaccine S19 [55].

Mallic and colleagues (2007) [56], in an attempt to improve the immunogenicity of *Brucella* antigens, demonstrated that the recombinant liposomized protein L7/L12 could induced strong cell immune response with increase of T cell proliferation, production of T_H1 cytokines and it could induced a strong humoral immune response. This strategy was also effective in improving the bacteria clearance after challenge with *B. abortus* 544, inducing protection levels comparable to S19 vaccine.

Live genetically modified microorganisms have been used as vector to stimulate host immune system recently. Recently, Harms and colleagues (2009) [57] developed a modified *E. coli* expressing invasion of *Yersinia* and listerialysin O (LLO) of *Listeria* capable to infect a range of cell types and to release *Brucella* antigens inside the host cell. They presented a vaccine vector that mimics the *Brucella* intracellular infection which induces the

differentiation to a T_H1 immune response and stimulates specific cytolytic T lymphocytes (CTLs).

As the gastrointestinal tract seems to be one of the main entrance to *Brucella* infection [58], Zhao and coworkers (2009) [59], used *Salmonella enterica* serovar Typhimurium, as a vaccine vector. When administrated orally, the vector is capable to express the ribosomal protein L7/L12 and the lumazine synthase enzyme (BLS). This treatment was able to stimulate the mucosal immunity and T_H1 mediated immunity. However, the levels of protection after *B. abortus* 544 challenge were lower than those encountered in vaccination with attenuated strain *B. abortus* 104M.

Cabrera and colleagues (2009) [60] constructed an infectious but replication-deficient Semliki Forest virus (SFV) particles carrying recombinant RNA encoding the *Brucella abortus* translation initiation factor 3 (IF3). BALB/c mice immunized with SFV-IF3 exhibited a significant level of resistance against challenge with the virulent *B. abortus* S2308, similarly to immunization with the live RB51 vaccine strain. Furthermore, SFV-IF3 immunization induced a T_H1 biased immune response with increased levels of IFN- γ and low levels of IL-4. These findings demonstrated the potential use this immunization approach to induce protection against *Brucella* infection.

DNA vaccines are considered an important strategy of vaccination that has been extensively investigated due the capacity to induce humoral and cell immune response [61]. Different *Brucella* genes have been evaluated through DNA vaccination [45, 51, 62-65]. However, until now, no monovalent DNA vaccine have demonstrated superior efficacy when compared to commercial vaccines [66]. In an attempt to produce an effective DNA vaccine against brucellosis, Luo *et al.* (2006) [67], developed a divalent DNA vaccine which codes for L7/L12 and Omp-16 proteins from *B. abortus*. As expected, this vaccine was able to induce a robust cell immune response with high T cell proliferation and IFN- γ production compared to Omp-16 or L7/L12 monovalent DNA vaccine, suggesting that these genes, together, can be a target for DNA vaccines. Also, the protection levels induced by Omp-16/L7L12 DNA vaccine were higher than those induced by monovalent preparations. However, the immunization with divalent Omp-16/ L7L12 can still provide less protection than the attenuated rough strain *B. abortus* RB51.

Cassataro *et al.* (2007) [68] demonstrated that a chimera with the scaffold protein BLS decorated with ten copies of a B and Th1 epitope derived from the Omp31 protein induced similar protection than Rev.1 vaccination against *B. ovis* infection. After this, they investigated the immunogenicity and protective capacity of the chimera as a DNA vaccine. Their results demonstrated that the addition of an immunodominant epitope to the N-termini of BLS significantly improved the degree of protection achieved by each immunogen individually. In contrast, immunization with both antigens (pcDNABLS and pCIOMP31) showed no additive or synergic effect on protection compared with the use of single antigen (Ags), independently of the immunization system used (DNA or recombinant protein immunization). Strikingly, the chimera as a DNA vaccine induced significantly higher protection against *B. ovis* than the Rev.1 vaccine, which contains all Ags of *Brucella* spp.

The chimera as a DNA vaccine also induced statistically similar levels of protection than the control vaccine Rev.1 against *B. melitensis*. Moreover, this vaccine also elicited long term protection against smooth and rough *Brucella* tested at 5 months after immunization [69].

Additionally, Yu and coworkers (2007) [66], constructed a combined DNA vaccine containing genes that codes for BCSP31, superoxide dismutase and L7/L12 antigens. The immunization with this group of genes stimulated a strong humoral immune response with higher induction of specific IgG, considerable IFN- γ and TNF- α production and the accumulation of CD8⁺ T lymphocytes. This combined vaccine was able to induce superior levels of protection when compared to live vaccine strains (S19 and RB51), suggesting the use of it in immunization of large animals. In another interesting study, Hu and coworkers (2009) [70] demonstrated that a combined DNA vaccine protects cattle against two infectious diseases, Brucellosis and Tuberculosis. The researchers constructed a DNA vaccine containing six genes encoding immunodominant antigens from *Mycobacterium bovis* (Ag85B, MPT64 and MPT83) and *Brucella abortus* (BCSP31, SOD and L7/L12). Vaccination with this preparation induced higher serum concentrations of both IFN- γ and IgG antibodies in addition to the improved CD4⁺ T cell-responses. Moreover, significantly enhancement of protection was observed comparing the BCG vaccine against *M. bovis* and protection levels of S19 vaccine strain against *B. abortus*.

CONCLUDING REMARKS

Brucellosis, in particular infections with *Brucella abortus*, *Brucella melitensis* or *Brucella suis*, remains a significant human health threat in many areas of the world. *Brucella* is recognized by host cells via TLR2, TLR4, and TLR9. However, TLR9 seems to be the most important innate immune receptor in controlling *Brucella* infection *in vivo*. Regarding cellular immunity, CD4⁺ and CD8⁺ T cells are important subsets involved in protection. However, our group has reported the more prominent role of CD8⁺ over CD4⁺ T lymphocytes and this might be due to the intracellular localization of *Brucella*. More recently, NKT and $\gamma\delta$ T cells were also identified as important components of host immune response. The prevention of human brucellosis predominantly depends on the eradication of the disease in their primary hosts. Currently used programs to eradicate brucellosis in cattle, sheep and goats rely on live attenuated vaccines. The virulence of those vaccine strains is nevertheless often high enough to cause abortion if administered to pregnant animals, and may be infectious for persons handling and administering the vaccine. Therefore, the development of effective vaccines that successfully protect the different hosts of *Brucella* without interfering with serodiagnostic remains a challenge. Additionally, there is a feeling among *Brucella* scientists that a genetically engineered live-attenuated vaccine might be the best option to replace current available commercial vaccines. However, we have to be aware of the difficulties regarding approval of such vaccine in regulatory agencies worldwide.

ACKNOWLEDGEMENTS

This work was supported by grants from FAPEMIG, CNPq, CNPq/Prosul (#490485/2007-3), CNPq/ANPCy (#490528/2008-2), and INCT-Vacinas (CNPq/FAPEMIG).

REFERENCES

- Corbel MJ, Morgan WJB. Genus *Brucella* Meyer and Shaw. In: Holt JG, Ed. Bergey's Manual of Systematic Bacteriology 1984.
- Pappas G, Akritidis N, Bosilkovski M, et al. Brucellosis. *N Engl J Med* 2005; 352(22): 2325-36.
- Olsen SC, Stoffregen WS. Essential role of vaccines in brucellosis control and eradication programs for livestock. *Expert Rev Vaccines* 2005; 4: 915-28.
- Dornand J, Gross A, Lafont V, et al. The innate immune response against *Brucella* in humans. *Vet Microbiol* 2002; 90: 383-94.
- Golding B, Scott DE, Scharf O, et al. Immunity and protection against *Brucella abortus*. *Microbes Infect* 2001; 3: 43-8.
- Oliveira SC, Harms JS, Rech EL, et al. The role of T cell subsets and cytokines in the regulation of intracellular bacterial infection. *Braz J Med Biol Res* 1998; 31: 77-84.
- Oliveira SC, Splitter GA. CD8⁺ type 1 CD44hi CD45 RBlo T lymphocytes control intracellular *Brucella abortus* infection as demonstrated in major histocompatibility complex class I- and class II-deficient mice. *Eur J Immunol* 1995; 25: 2551-7.
- Jiang X, Baldwin CL. Effects of cytokines on intracellular growth of *Brucella abortus*. *Infect Immun* 1993; 61: 124-34.
- Fernandes DM, Jiang X, Jung JH, et al. Comparison of T cell cytokines in resistant and susceptible mice infected with virulent *Brucella abortus* strain 2308. *FEMS Immunol Med Microbiol* 1996; 16: 193-203.
- Li HZ. A pathohistological study on experimental brucellosis in inbred mice. *Zhonghua Bing Li Xue Za Zhi*. 1991; 20: 134-6.
- Montaraz JA, Winter AJ. Comparison of living and nonliving vaccines for *Brucella abortus* in BALB/c mice. *Infect Immun* 1986; 53: 245-51.
- Sathiyaseelan J, Goenka R, Parent M, et al. Treatment of *Brucella*-susceptible mice with IL-12 increases primary and secondary immunity. *Cell Immunol* 2006; 243: 1-9.
- Barrionuevo P, Cassataro J, Delpino MV, et al. *Brucella abortus* inhibits major histocompatibility complex class II expression and antigen processing through interleukin-6 secretion via Toll-like receptor 2. *Infect Immun* 2008; 76: 250-62.
- Bessoles S, Dudal S, Besra GS, et al. Human CD4⁺ invariant NKT cells are involved in antibacterial immunity against *Brucella suis* through CD1d-dependent but CD4-independent mechanisms. *Eur J Immunol* 2009; 39: 1025-35.
- Dudal S, Turriere C, Bessoles S, et al. Release of LL-37 by activated human Vgamma9Vdelta2 T cells: a microbicidal weapon against *Brucella suis*. *J Immunol* 2006; 177: 5533-9.
- Oliaro J, Dudal S, Liautard J, et al. Vgamma9Vdelta2 T cells use a combination of mechanisms to limit the spread of the pathogenic bacteria *Brucella*. *J Leukoc Biol* 2005; 77: 652-60.
- Riley LK, Robertson DC. Ingestion and intracellular survival of *Brucella abortus* in human and bovine polymorphonuclear leukocytes. *Infect Immun* 1984; 46: 224-30.
- Kreutzer DL, Dreyfus LA, Robertson DC. Interaction of polymorphonuclear leukocytes with smooth and rough strains of *Brucella abortus*. *Infect Immun* 1979; 23: 737-42.
- Zwerdling A, Delpino MV, Pasquevich KA, et al. *Brucella abortus* activates human neutrophils. *Microbes Infect* 2009; 11: 689-97.
- Kawai T, Akira S. TLR signaling. *Semin Immunol* 2007; 19: 24-32.
- Medzhitov R. Recognition of microorganisms and activation of the immune response. *Nature* 2007; 449: 819-26.
- Kawai T, Akira S. Signaling to NF-kappaB by Toll-like receptors. *Trends Mol Med* 2007; 13: 460-9.
- Campos MA, Rosinha GM, Almeida IC, et al. Role of Toll-like receptor 4 in induction of cell-mediated immunity and resistance to *Brucella abortus* infection in mice. *Infect Immun* 2004; 72: 176-86.

- [24] Barquero-Calvo E, Chaves-Olarte E, Weiss DS, *et al.* *Brucella abortus* uses a stealthy strategy to avoid activation of the innate immune system during the onset of infection. *PLoS One* 2007; 2: 631.
- [25] Giambartolomei GH, Zwerdling A, Cassataro J, *et al.* Lipoproteins, not lipopolysaccharide, are the key mediators of the proinflammatory response elicited by heat-killed *Brucella abortus*. *J Immunol* 2004; 173: 4635-42.
- [26] Zwerdling A, Delpino MV, Barrionuevo P, *et al.* *Brucella* lipoproteins mimic dendritic cell maturation induced by *Brucella abortus*. *Microbes Infect* 2008; 10: 1346-54.
- [27] Macedo GC, Magnani DM, Carvalho NB, *et al.* Central role of MyD88-dependent dendritic cell maturation and proinflammatory cytokine production to control *Brucella abortus* infection. *J Immunol* 2008; 180: 1080-7.
- [28] Copin R, De Baetselier P, Carlier Y, *et al.* MyD88-dependent activation of B220-CD11b+LY-6C+ dendritic cells during *Brucella melitensis* infection. *J Immunol* 2007; 178: 5182-91.
- [29] Weiss DS, Takeda K, Akira S, *et al.* MyD88, but not toll-like receptors 4 and 2, is required for efficient clearance of *Brucella abortus*. *Infect Immun* 2005; 73: 5137-43.
- [30] Adams LG. Development of live *Brucella* vaccines. In: Adams LG, ed. *Advances in brucellosis research*. Texas: A & M University Press 1990; pp. 205-76.
- [31] Nicoletti P. Vaccination. In: Nielsen K, Dunca JR, Eds. *Animal Brucellosis*. Boca Raton: CRC Press 1990; pp. 284-99.
- [32] Schurig GG, Roop RM 2nd, Bagchi T, *et al.* Biological properties of RB51; a stable rough strain of *Brucella abortus*. *Vet Microbiol* 1991; 28: 171-88.
- [33] Ariza J. Brucellosis: an update. The perspective from the Mediterranean basin. *Rev Med Microbiol* 1999; 10: 125-35.
- [34] Moriyon I, Grillo MJ, Monreal D, *et al.* Rough vaccines in animal brucellosis: structural and genetic basis and present status. *Vet Res* 2004; 35: 1-38.
- [35] Grillo MJ, Manterola L, de Miguel MJ, *et al.* Increases of efficacy as vaccine against *Brucella abortus* infection in mice by simultaneous inoculation with avirulent smooth bvrS/bvrR and rough wbkA mutants. *Vaccine* 2006; 24: 2910-6.
- [36] Arenas-Gamboa AM, Ficht TA, Kahl-McDonagh MM, *et al.* The *Brucella abortus* S19 Deltavjbr live vaccine candidate is safer than S19 and confers protection against wild-type challenge in BALB/c mice when delivered in a sustained-release vehicle. *Infect Immun* 2009; 77: 877-84.
- [37] Izadjoo MJ, Bhattacharjee AK, Paranavitana CM, *et al.* Oral vaccination with *Brucella melitensis* WR201 protects mice against intranasal challenge with virulent *Brucella melitensis* 16M. *Infect Immun* 2004; 72: 4031-9.
- [38] Izadjoo MJ, Mense MG, Bhattacharjee AK, *et al.* A study on the use of male animal models for developing a live vaccine for brucellosis. *Transbound Emerg Dis* 2008; 55(3-4): 145-51.
- [39] Grillo MJ, Marin CM, Barberan M, *et al.* Efficacy of bp26 and bp26/omp31 *B. melitensis* Rev.1 deletion mutants against *Brucella ovis* in rams. *Vaccine* 2009; 27:187-91.
- [40] Cassataro J, Pasquevich K, Bruno L, *et al.* Antibody reactivity to Omp31 from *Brucella melitensis* in human and animal infections by smooth and rough Brucellae. *Clin Diagn Lab Immunol* 2004; 11(1): 111-4.
- [41] Zygmunt MS, Baucheron S, Vizcaino N, *et al.* Single-step purification and evaluation of recombinant BP26 protein for serological diagnosis of *Brucella ovis* infection in rams. *Vet Microbiol* 2002; 87(3): 213-20.
- [42] Cloeckaert A, Baucheron S, Vizcaino N, *et al.* Use of recombinant BP26 protein in serological diagnosis of *Brucella melitensis* infection in sheep. *Clin Diagn Lab Immunol* 2001; 8(4): 772-5.
- [43] Adone R, Francia M, Ciuchini F. Evaluation of *Brucella melitensis* B115 as rough-phenotype vaccine against *B. melitensis* and *B. ovis* infections. *Vaccine* 2008; 26: 4913-7.
- [44] Schurig GG, Sriranganathan N, Corbel MJ. Brucellosis vaccines: past, present and future. *Vet Microbiol* 2002; 90(1-4): 479-96.
- [45] Al-Mariri A, Tibor A, Mertens P, *et al.* Protection of BALB/c mice against *Brucella abortus* 544 challenge by vaccination with bacterioferritin or P39 recombinant proteins with CpG oligodeoxynucleotides as adjuvant. *Infect Immun* 2001; 69: 4816-22.
- [46] Tabatabai LB, Pugh GW Jr. Modulation of immune responses in Balb/c mice vaccinated with *Brucella abortus* Cu-Zn superoxide dismutase synthetic peptide vaccine. *Vaccine* 1994; 12: 919-24.
- [47] Oliveira SC, Splitter GA. Immunization of mice with recombinant L7/L12 ribosomal protein confers protection against *Brucella abortus* infection. *Vaccine* 1996; 14: 959-62.
- [48] Oliveira SC, Zhu Y, Splitter G. Sequences of the rpJL operon containing the L10 and L7/L12 genes from *Brucella abortus*. *Gene* 1994; 140: 137-8.
- [49] Oliveira SC, Zhu Y, Splitter GA. Recombinant L7/L12 ribosomal protein and gamma-irradiated *Brucella abortus* induce a T-helper 1 subset response from murine CD4+ T cells. *Immunology* 1994; 83: 659-64.
- [50] Oliveira SC, Harms JS, Banai M, *et al.* Recombinant *Brucella abortus* proteins that induce proliferation and gamma-interferon secretion by CD4+ T cells from *Brucella*-vaccinated mice and delayed-type hypersensitivity in sensitized guinea pigs. *Cell Immunol* 1996; 172: 262-8.
- [51] Velikovskiy CA, Cassataro J, Giambartolomei GH, *et al.* A DNA vaccine encoding lumazine synthase from *Brucella abortus* induces protective immunity in BALB/c mice. *Infect Immun* 2002; 70: 2507-11.
- [52] Cassataro J, Estein SM, Pasquevich KA, *et al.* Vaccination with the recombinant *Brucella* outer membrane protein 31 or a derived 27-amino-acid synthetic peptide elicits a CD4+ T helper 1 response that protects against *Brucella melitensis* infection. *Infect Immun* 2005; 73: 8079-88.
- [53] Rosinha GM, Myioshi A, Azevedo V, *et al.* Molecular and immunological characterisation of recombinant *Brucella abortus* glyceraldehyde-3-phosphate-dehydrogenase, a T- and B-cell reactive protein that induces partial protection when co-administered with an interleukin-12-expressing plasmid in a DNA vaccine formulation. *J Med Microbiol* 2002; 51: 661-71.
- [54] Pasquevich KA, Estein SM, Garcia Samartino C, *et al.* Immunization with recombinant *Brucella* species outer membrane protein Omp16 or Omp19 in adjuvant induces specific CD4+ and CD8+ T cells as well as systemic and oral protection against *Brucella abortus* infection. *Infect Immun* 2009; 77: 436-45.
- [55] Delpino MV, Estein SM, Fossati CA, *et al.* Vaccination with *Brucella* recombinant DnaK and SurA proteins induces protection against *Brucella abortus* infection in BALB/c mice. *Vaccine* 2007; 25: 6721-9.
- [56] Mallick AI, Singha H, Chaudhuri P, *et al.* Liposomised recombinant ribosomal L7/L12 protein protects BALB/c mice against *Brucella abortus* 544 infection. *Vaccine* 2007; 25: 3692-704.
- [57] Harms JS, Durward MA, Magnani DM, *et al.* Evaluation of recombinant invasive, non-pathogenic *Escherichia coli* as a vaccine vector against the intracellular pathogen, *Brucella*. *J Immune Based Ther Vaccines* 2009; 7: 1.
- [58] Gorvel JP, Moreno E, Moriyon I. Is *Brucella* an enteric pathogen? *Nat Rev Microbiol* 2009; 7: 250; author reply
- [59] Zhao Z, Li M, Luo D, *et al.* Protection of mice from *Brucella* infection by immunization with attenuated *Salmonella enterica* serovar typhimurium expressing A L7/L12 and BLS fusion antigen of *Brucella*. *Vaccine* 2009; 27: 5214-9.
- [60] Cabrera A, Saez D, Cespedes S, *et al.* Vaccination with recombinant Semliki Forest virus particles expressing translation initiation factor 3 of *Brucella abortus* induces protective immunity in BALB/c mice. *Immunobiology* 2009; 214(6): 467-74.
- [61] Leclercq S, Harms JS, Oliveira SC. Enhanced efficacy of DNA vaccines against an intracellular bacterial pathogen by genetic adjuvants. *Curr Pharm Biotechnol* 2003; 4: 99-107.
- [62] Kurar E, Splitter GA. Nucleic acid vaccination of *Brucella abortus* ribosomal L7/L12 gene elicits immune response. *Vaccine* 1997; 15: 1851-7.
- [63] Onate AA, Cespedes S, Cabrera A, *et al.* A DNA vaccine encoding Cu,Zn superoxide dismutase of *Brucella abortus* induces protective immunity in BALB/c mice. *Infect Immun* 2003; 71: 4857-61.
- [64] Mayfield JE, Bricker BJ, Godfrey H, *et al.* The cloning, expression, and nucleotide sequence of a gene coding for an immunogenic *Brucella abortus* protein. *Gene* 1988; 63: 1-9.
- [65] Cassataro J, Velikovskiy CA, de la Barrera S *et al.* A DNA vaccine coding for the *Brucella* outer membrane protein 31 confers protection against *B. melitensis* and *B. ovis* infection by eliciting a specific cytotoxic response. *Infect Immun* 2005; 73: 6537-46.

- [66] Yu DH, Hu XD, Cai H. A combined DNA vaccine encoding BCSP31, SOD, and L7/L12 confers high protection against *Brucella abortus* 2308 by inducing specific CTL responses. *DNA Cell Biol* 2007; 26: 435-43.
- [67] Luo D, Ni B, Li P, *et al.* Protective immunity elicited by a divalent DNA vaccine encoding both the L7/L12 and Omp16 genes of *Brucella abortus* in BALB/c mice. *Infect Immun* 2006; 74: 2734-41.
- [68] Cassataro J, Pasquevich KA, Estein SM, *et al.* A recombinant subunit vaccine based on the insertion of 27 amino acids from Omp31 to the N-terminus of BLS induced a similar degree of protection against *B. ovis* than Rev.1 vaccination. *Vaccine* 2007; 25: 4437-46.
- [69] Cassataro J, Pasquevich KA, Estein SM, *et al.* A DNA vaccine coding for the chimera BLSOmp31 induced a better degree of protection against *B. ovis* and a similar degree of protection against *B. melitensis* than Rev.1 vaccination. *Vaccine* 2007; 25: 5958-67.
- [70] Hu XD, Yu DH, Chen ST, *et al.* A combined DNA vaccine provides protective immunity against *Mycobacterium bovis* and *Brucella abortus* in cattle. *DNA Cell Biol* 2009; 28: 191-9.

Received: September 18, 2009

Revised: February 8, 2010

Accepted: August 30, 2010

© Oliveira *et al.*; Licensee Bentham Open.

This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/3.0/>) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.